Match tier Listed
Presence Current · Arkansas
Last published 2025
Sources OpenAlex · ORCID
Refreshed 2026-10-06

Timothy C. Chambers

High Impact

Role not yet determined Is this you? Add your title

Also affiliated: Rush University Medical Center (1994); Merck & Co., Inc., Rahway, NJ, USA (United States) (1988–1990); Emory University (1990–1994); Gdańsk University of Technology (2012); University of Arkansas Medical Center (2012); National Jewish Health (1986–1992); Winship Cancer Institute (1993); University of Colorado Anschutz (1990); University of Colorado Denver (1990)

35 h-index 161 pubs 4,732 cited

  • Humans
  • Phosphorylation
  • Apoptosis
  • Vinblastine
  • Cell Line, Tumor
  • Animals
  • Mitosis
  • Tumor Cells, Cultured
  • Antineoplastic Agents
  • Cell Survival
  • Antineoplastic Agents, Phytogenic
  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Protein Kinase C
  • Proto-Oncogene Proteins c-bcl-2
  • Mitogen-Activated Protein Kinases

Biography and Research Information

OverviewAI-generated summary

Timothy C. Chambers' research focuses on the molecular mechanisms underlying cellular responses to chemotherapeutic agents and the pathways involved in programmed cell death, or apoptosis. His work has investigated the role of specific signaling cascades, such as the JNK and ERK pathways, in mediating cellular fate following treatment with drugs like vinblastine and adriamycin. He has characterized the phosphorylation of key proteins, including Bcl-2, Bcl-XL, and P-glycoprotein, and identified the kinases responsible for these modifications, such as JNK and protein kinase C.

Chambers' research group has explored how these signaling events correlate with cellular outcomes, including mitotic arrest and cell survival. His publications detail the differential effects of microtubule inhibitors on mitogen-activated protein kinase (MAPK) pathways in tumor cells. He has also investigated the functional consequences of P-glycoprotein phosphorylation in multidrug-resistant cells, contributing to the understanding of drug resistance mechanisms.

With an h-index of 35, 167 total publications, and over 4,700 citations, Chambers is recognized as a highly cited researcher. He collaborates with colleagues at the University of Arkansas for Medical Sciences, including Joshua M. Eichhorn, Alicja Urbaniak, Megan R. Reed, and Billie Heflin, with whom he has co-authored multiple publications.

Metrics

  • h-index: 35
  • Publications: 161
  • Citations: 4,732

Selected Publications

  • Evaluation of the Activity of Monensin and Its Analogs for Modulation of Stem-like Cell Functionality in 2D and 3D Breast Cancer Models (2025)
    ACS Pharmacology & Translational Science 1 citation DOI OpenAlex
  • Multicellular tumor-stromal interactions recapitulate aspects of therapeutic response and human oncogenic signaling in a 3D disease model for H3K27M-altered DIPG (2025)
    Oncogene 7 citations DOI OpenAlex
  • Monensin and Its Analogs Exhibit Activity Against Breast Cancer Stem-Like Cells in an Organoid Model (2025)
    bioRxiv (Cold Spring Harbor Laboratory) DOI OpenAlex
  • Data from Key role for Bak activation and Bak-Bax interaction in the apoptotic response to vinblastine (2023)
  • Anti-glioblastoma activity of monensin and its analogs in an organoid model of cancer (2022)
    Biomedicine & Pharmacotherapy 25 citations DOI OpenAlex
  • Monensin and its analogues show anti‐glioblastoma activity in an organoid model of cancer (2022)
    The FASEB Journal DOI OpenAlex
  • Primary acute lymphoblastic leukemia cells are susceptible to microtubule depolymerization in G1 and M phases through distinct cell death pathways (2022)
    Journal of Biological Chemistry 3 citations DOI OpenAlex
  • Phosphoproteomics Provides Novel Insights into the Response of Primary Acute Lymphoblastic Leukemia Cells to Microtubule Depolymerization in G1 Phase of the Cell Cycle (2021)
    ACS Omega 1 citation DOI OpenAlex
  • Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models (2021)
    Biomedicine & Pharmacotherapy 13 citations DOI OpenAlex
  • Abstract PS18-46: Inhibition of breast cancer stem cells in 2- and 3-dimensional culture by novel salinomycin analogs (2021)
    Cancer Research DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

198 Collaborators 39 Institutions 11 Countries

Top Collaborators

View profile →
View profile →

Similar Researchers

Based on overlapping research topics